Data / Form D filings / SYNTIS BIO, INC.
SYNTIS BIO, INC.: Form D filings
SYNTIS BIO, INC., a biotechnology company in Boston, MA, filed 4 Form D notices with the SEC between 2022 and 2025. The latest, on July 2, 2025, reports $25 million sold of a $26.5 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 135 MORRISSEY BLVD, SUITE 101A, Boston, MA, 02125
- Phone
- (857) 675-1109
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1943061
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 2, 2025 | New notice | $26,483,445 | $24,983,429 | $1,500,016 | 12 | Jun 17, 2025 | sec.gov |
| Jan 27, 2025 | New notice | $9,000,000 | $6,316,555 | $2,683,445 | 9 | Dec 30, 2024 | sec.gov |
| Jan 17, 2023 | Amendment | $15,372,179 | $15,372,179 | 15 | Aug 3, 2022 | sec.gov | |
| Aug 17, 2022 | New notice | $11,189,985 | $11,189,985 | 12 | Aug 3, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Chenny Zhang | Director | |
| Martin Madaus | Director | |
| Carlo Giovanni Traverso | Director | |
| Robert Langer | Director | |
| Teymour Boutros-Ghali | Director | |
| Teymour Boutros-Ghali | Director | |
| Rahul Dhanda | Executive Officer, Director | |
| Michael Nannizzi | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Jun 30, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what SYNTIS BIO, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.